Literature DB >> 1506336

A comparison of the costs of ceftazidime therapy and gentamicin combinations in three UK hospitals.

M Malek1, W Lynch, N Wells, T Elliott, A Bint, P Sanderson, M Jaderberg, P Davey.   

Abstract

This study compares the utilization costs of ceftazidime therapy with those of gentamicin in combination with other antibacterial drugs. The results show that the relatively high purchase cost of ceftazidime compared to combinations is more than counterbalanced by the additional materials used for drug administration and serum antibiotic assays, even when other drugs were combined with ceftazidime. The average drug and equipment costs were 230.13 pounds for ceftazidime regimens and 253.94 pounds for gentamicin regimens. It is also shown that ceftazidime therapy is associated with a reduction in personnel time compared to gentamicin regimens. The average times per patient for administration and assay were 1 h 43 min for ceftazidime and 4 h 57 min for gentamicin regimens. We conclude that ceftazidime regimens are cheaper than gentamicin regimens when all drug and equipment costs are quantified. Moreover, the use of ceftazidime will release staff time for other purposes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1506336     DOI: 10.1093/jac/29.2.207

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

Review 1.  Pharmacoeconomics of intravenous drug administration.

Authors:  S E Parker; P G Davey
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

Review 2.  Pharmacoeconomics of antibacterial treatment.

Authors:  P G Davey; M M Malek; S E Parker
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

3.  Current principles and application of pharmacoeconomics.

Authors:  M Malek
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

4.  Defining criteria for the pharmacoeconomic evaluation of new oral cephalosporins.

Authors:  P G Davey; M Malek
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

5.  Third generation cephalosporins in the parenteral to oral switch.

Authors:  D Rimmer
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

6.  Cost comparison of antibacterial therapies for serious infections. A New Zealand 3-hospital study.

Authors:  W G Scott; H M Scott; S Henderson; A Inder; J Sanders; R Spearing; C McArthur; J Judson; B Baker; P Hicks; P Cotterell
Journal:  Pharmacoeconomics       Date:  1999-08       Impact factor: 4.981

7.  Cost of gentamicin assays carried out by microbiology laboratories.

Authors:  P F Vacani; M M Malek; P G Davey
Journal:  J Clin Pathol       Date:  1993-10       Impact factor: 3.411

Review 8.  Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.

Authors:  A Adu; C L Armour
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 9.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

10.  Ceftazidime versus aminoglycoside and (ureido)penicillin combination in the empirical treatment of serious infection.

Authors:  N Finer; P Goustas
Journal:  J R Soc Med       Date:  1992-09       Impact factor: 18.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.